stockrowANI Pharmaceuticals, Inc. (ANIP) vs HUTCHMED (China) Limited Sponsored ADR (HCM)
- ANI Pharmaceuticals, Inc. ANIP 69.03 −3.66%
- HUTCHMED (China) Limited Sponsored ADR HCM 14.27 +2.51%
ANI Pharmaceuticals, Inc. and HUTCHMED (China) Limited Sponsored ADR are both Drug Manufacturers Specialty & Generic companies. HUTCHMED (China) Limited Sponsored ADR is the larger, with a market value of $2.5B against $1.6B — 1.6× the size. HUTCHMED (China) Limited Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; ANI Pharmaceuticals, Inc. trades at 13.3×. HUTCHMED (China) Limited Sponsored ADR grew revenue faster over the last twelve months: 245.2% against 25.9%. ANI Pharmaceuticals, Inc. has the higher net margin (11.2% vs −23.6%) and the higher return on invested capital (46.4% vs 0.00%). Across the 17 metrics below, ANI Pharmaceuticals, Inc. leads on 12 and HUTCHMED (China) Limited Sponsored ADR on 5.
Valuation
Profitability
| Metric | ANIP | HCM | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 61.06% | 44.40% | 53.51% |
| Operating margin | 15.99% | 0.00% | 0.00% |
| Net margin | 11.22% | (23.63%) | (2.45%) |
| Free cash flow margin | 19.72% | 0.00% | 0.00% |
| Return on equity | 20.45% | 0.00% | (0.80%) |
| Return on assets | 7.85% | 0.00% | (1.67%) |
| Return on invested capital | 46.43% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack